PE20211395A1 - Proceso de preparacion de dos derivados de 4-{[(2s)-2-{4-[5-cloro-2-(1h-1,2,3-triazol-1-il)fenil]-5-metoxi-2-oxopiridin-1(2h)-il}butanoil]amino}-2-fluorobenzamida - Google Patents

Proceso de preparacion de dos derivados de 4-{[(2s)-2-{4-[5-cloro-2-(1h-1,2,3-triazol-1-il)fenil]-5-metoxi-2-oxopiridin-1(2h)-il}butanoil]amino}-2-fluorobenzamida

Info

Publication number
PE20211395A1
PE20211395A1 PE2020001408A PE2020001408A PE20211395A1 PE 20211395 A1 PE20211395 A1 PE 20211395A1 PE 2020001408 A PE2020001408 A PE 2020001408A PE 2020001408 A PE2020001408 A PE 2020001408A PE 20211395 A1 PE20211395 A1 PE 20211395A1
Authority
PE
Peru
Prior art keywords
chloro
triazol
phenyl
fluorobenzamide
amino
Prior art date
Application number
PE2020001408A
Other languages
English (en)
Inventor
Julian Egger
Daniel Gotz
Michal Sowa
Original Assignee
Bayer Ag
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Bayer Pharma AG filed Critical Bayer Ag
Publication of PE20211395A1 publication Critical patent/PE20211395A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms

Abstract

La presente invencion se refiere a un proceso para preparar 4-{[(2S)-2-{4-[5-cloro-2-(4-cloro-1H-1,2,3-triazol-1-il)fenil]-5-metoxi-2-oxopiridin-1(2H)-il}butanoil]amino}-2-fluorobenzamida (formula I) o 4-({(2S)-2-[4-{5-cloro-2-[4-(trifluorometil)-1H-1,2,3-triazol-1-il]fenil}-5-metoxi-2-oxopiridin-1(2H)-il]butanoil}amino)-2-fluorobenzamida (formula II), caracterizado porque 4-[5-cloro-2-(4-cloro-1H-1,2,3-triazol-1-il)fenil]-5-metoxipiridin-2(1H)-ona (XVI-Cl) o 4-{5-cloro-2-[4-(trifluorometil)-1H-1,2,3-triazol-1-il]fenil}-5-metoxipiridin-2(1H)-ona (XVI-CF3) se hace reaccionar con 4-{[(2R)-2-bromobutanoil]amino}-2-fluorobenzamida (XIX) en presencia de una base en un solvente, posteriormente se aisla el compuesto de la formula (I) o (II).
PE2020001408A 2018-03-15 2019-03-08 Proceso de preparacion de dos derivados de 4-{[(2s)-2-{4-[5-cloro-2-(1h-1,2,3-triazol-1-il)fenil]-5-metoxi-2-oxopiridin-1(2h)-il}butanoil]amino}-2-fluorobenzamida PE20211395A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18161983 2018-03-15
PCT/EP2019/055815 WO2019175043A1 (en) 2018-03-15 2019-03-08 Preparative process of two 4-{[(2s)-2-{4-[5-chloro-2-(1h-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2h)-yl}butanoyl]amino}-2-fluorobenzamide derivatives

Publications (1)

Publication Number Publication Date
PE20211395A1 true PE20211395A1 (es) 2021-07-27

Family

ID=61683650

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020001408A PE20211395A1 (es) 2018-03-15 2019-03-08 Proceso de preparacion de dos derivados de 4-{[(2s)-2-{4-[5-cloro-2-(1h-1,2,3-triazol-1-il)fenil]-5-metoxi-2-oxopiridin-1(2h)-il}butanoil]amino}-2-fluorobenzamida

Country Status (28)

Country Link
US (1) US11542245B2 (es)
EP (2) EP3889147A1 (es)
JP (1) JP7287978B2 (es)
KR (1) KR20200131241A (es)
CN (1) CN111770917B (es)
AR (1) AR117400A1 (es)
AU (1) AU2019236369B2 (es)
BR (1) BR112020018562A2 (es)
CA (1) CA3093733A1 (es)
CL (1) CL2020002371A1 (es)
DK (1) DK3765452T3 (es)
ES (1) ES2920449T3 (es)
HR (1) HRP20220565T1 (es)
HU (1) HUE058796T2 (es)
IL (2) IL300463A (es)
JO (1) JOP20200232B1 (es)
LT (1) LT3765452T (es)
MX (1) MX2020009580A (es)
PE (1) PE20211395A1 (es)
PL (1) PL3765452T3 (es)
PT (1) PT3765452T (es)
RS (1) RS63338B1 (es)
SG (1) SG11202006710RA (es)
SI (1) SI3765452T1 (es)
TW (1) TWI823911B (es)
UA (1) UA126940C2 (es)
UY (1) UY38147A (es)
WO (1) WO2019175043A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220140558A (ko) * 2020-02-11 2022-10-18 케미노바 에이/에스 (r)-2-아미노부탄산으로부터 s-베플루부타미드를 합성하는 방법
EP4304714A1 (en) 2021-03-09 2024-01-17 Bayer Aktiengesellschaft Crystalline forms of (4s)-2 4-chloro-4-ethyl-7 3-fluoro-3 5-methoxy-3 2,5-dioxo-1 4-(trifluoromethyl)-3 2h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-5 dibenzenaheptaphane-7 4-carboxamide
WO2022189280A1 (en) 2021-03-09 2022-09-15 Bayer Aktiengesellschaft Solvates of (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoro-methyl)-32 h-6- aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide
CA3212644A1 (en) 2021-03-09 2022-09-15 Bayer Aktiengesellschaft Pharmaceutical dosage forms comprising (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5- dioxo-14-(trifluoromethyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)- dibenzenaheptaphane-74-carboxamide
WO2023174399A1 (zh) * 2022-03-18 2023-09-21 苏州晶云药物科技股份有限公司 取代的氧代吡啶类衍生物的晶型及其制备方法
CN116535392B (zh) * 2023-06-26 2023-09-05 成都施贝康生物医药科技有限公司 一种氧代吡啶类化合物的制备方法及中间体和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2396079A1 (en) 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
TWI633089B (zh) 2013-03-28 2018-08-21 拜耳製藥股份有限公司 經取代的酮基吡啶衍生物
JO3703B1 (ar) * 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
CN107793396B (zh) 2016-08-31 2021-02-26 江苏恒瑞医药股份有限公司 环氧基取代的氧代吡啶类衍生物、其制备方法及其在医药上的应用
EP3898611A1 (en) * 2018-12-17 2021-10-27 Bayer Aktiengesellschaft Substituted oxopyridine derivatives for the treatment and/or prophylaxis of thrombotic or thromboembolic disorders and/or thrombotic or thromboembolic complications
EP3898634A1 (en) * 2018-12-21 2021-10-27 Bayer Aktiengesellschaft Substituted oxopyridine derivatives
MA54521A (fr) * 2018-12-21 2022-03-30 Bayer Ag Dérivés d'oxopyridine substitués

Also Published As

Publication number Publication date
CA3093733A1 (en) 2019-09-19
SI3765452T1 (sl) 2022-06-30
EP3765452A1 (en) 2021-01-20
ES2920449T3 (es) 2022-08-04
JOP20200232B1 (ar) 2023-09-17
IL277240B1 (en) 2023-09-01
JOP20200232A1 (ar) 2020-09-14
TWI823911B (zh) 2023-12-01
PL3765452T3 (pl) 2022-08-01
KR20200131241A (ko) 2020-11-23
RU2020133706A (ru) 2022-04-18
HUE058796T2 (hu) 2022-09-28
JP2021517573A (ja) 2021-07-26
JP7287978B2 (ja) 2023-06-06
AU2019236369A1 (en) 2020-07-30
UY38147A (es) 2019-10-01
DK3765452T3 (da) 2022-06-27
EP3765452B1 (en) 2022-04-13
IL277240B2 (en) 2024-01-01
UA126940C2 (uk) 2023-02-22
US11542245B2 (en) 2023-01-03
HRP20220565T1 (hr) 2022-06-10
CN111770917B (zh) 2023-09-26
LT3765452T (lt) 2022-05-25
RS63338B1 (sr) 2022-07-29
EP3889147A1 (en) 2021-10-06
BR112020018562A2 (pt) 2020-12-29
AU2019236369B2 (en) 2024-04-18
WO2019175043A1 (en) 2019-09-19
IL300463A (en) 2023-04-01
US20210017152A1 (en) 2021-01-21
PT3765452T (pt) 2022-06-23
CN111770917A (zh) 2020-10-13
CL2020002371A1 (es) 2021-01-29
MX2020009580A (es) 2020-10-05
SG11202006710RA (en) 2020-08-28
AR117400A1 (es) 2021-08-04
IL277240A (en) 2020-10-29
TW202002969A (zh) 2020-01-16

Similar Documents

Publication Publication Date Title
PE20211395A1 (es) Proceso de preparacion de dos derivados de 4-{[(2s)-2-{4-[5-cloro-2-(1h-1,2,3-triazol-1-il)fenil]-5-metoxi-2-oxopiridin-1(2h)-il}butanoil]amino}-2-fluorobenzamida
HRP20210459T1 (hr) Supstituirani derivati oksopiridina
PE20211411A1 (es) Compuestos de anillo fusionado
PE20210642A1 (es) Inhibidores de pd-1/pd-l1
PE20170705A1 (es) Nuevos compuestos como inhibidores de ret (reorganizado durante la transfeccion)
CY1114242T1 (el) Μια διεργασια για την παρασκευη του υποκινητη αποπτωσης αβτ-263
PE20160115A1 (es) Compuestos derivados de imidazol como inhibidores de protein quinasa
CY1120907T1 (el) Αντιμυκητιασικοι παραγοντες
PE20141855A1 (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
PE20130385A1 (es) Derivados del acido naft-2-ilacetico para tratar el sida
NZ612544A (en) Heterocyclic compounds suitable for the treatment of dyslipidemia
PE20090984A1 (es) Inhibidores de peptido desformilasa
PE20191108A1 (es) Inhibidores selectivos de jak1
BR112018069461A2 (pt) nova forma cristalina de sal de 1-(5-(2,4-difluorofenil)-1-((3-fluorofenil)sulfonil)-4-metoxi-1h-pirrol-3-il)-n-metilmetanamina salt
PE20210859A1 (es) Inhibidores de triazol glicolato oxidasa
MX2020013311A (es) Composicion farmaceutica para administracion topica.
PE20070591A1 (es) Derivados de 6-heteroarilpiridoindolona y su preparacion
ES2421587T3 (es) Uso de derivados de pirimidilaminobenzamida para el tratamiento de mastocitosis sistémica
RU2007147957A (ru) Комбинация производных пиримидиламинобензамида и иматиниба для лечения или профилактики пролиферативных заболеваний
AR124183A1 (es) Mezclas que contienen metarilpicoxamid
BR112022005728A2 (pt) Compostos de tiazol carboxamida e seu uso para o tratamento de infecções micobacterianas
JP2021500350A5 (es)
EA201991337A1 (ru) Средство для лечения деменции различной этиологии
RU2022129311A (ru) Способ получения двух 4-{ [(2s)-2-{ 4-[5-хлор-2-(1h-1,2,3-триазол-1-ил)фенил]-5-метокси-2-оксопиридин-1(2h)-ил} бутаноил]амино} -2-фторбензамидных производных
TR201902314T4 (tr) Azol benzen türevi ve bunun kristali.